Novartis | NOVN - Assets


Novartis reported $118.53B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Alcon AG USD 31.62B 64M Mar/2026
Almirall EUR 2.34B 29.21M Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Autolus Therapeutics Ltd USD 527.06M 62M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Fresenius EUR 41.4B 1.07B Dec/2025
Fresenius Medical Care EUR 31.47B 465.26M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
GRIFOLS EUR 20.08B 366M Mar/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
J&J USD 200.89B 1.68B Mar/2026
Lakefront Biotherapeutics EUR 3.37B 34.09M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 53.07B 1.54B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Novo Nordisk DKK 559.22B 16.32B Mar/2026
Orion EUR 2.08B 69.2M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Philips EUR 27.27B 322M Mar/2026
Recordati EUR 5.33B 82.27M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
UCB EUR 18.16B 971M Dec/2025